C. Michael Gibson and Steven Goldberg discuss REDUCE-FMR and sham-controlled trials in MV repair.

C. Michael Gibson and Vinod Thourani discuss 5-year outcomes in this randomized trial of TAVR vs SAVR in intermediate-risk patients.

Suzanne Baron and C. Michael Gibson discuss important new details from these two structural heart disease trials.

C. Michael Gibson and Ajay Kirtane review the results of this single-arm stent study.

Roxana Mehran brings C. Michael Gibson up to speed on a campaign to promote talent in medicine by offering professional opportunities to female physicians.

Usman Baber, who led this thrombogenicity substudy, walks C. Michael Gibson through the key findings.

C. Michael Gibson and Myeong-Ki Hong discuss 5-year outcomes in this randomized trial.

What are the respective values of FFR and OCT in guiding revascularization? C. Michael Gibson gets a primer from Francesco Burzotta.

C. Michael Gibson connects with Sameer Mehta and Francisco Fernandez to hear how new tech is poised to disrupt medical care.

C. Michael Gibson learns about the Onyx ONE trial from Stephan Windecker.